$18.37
1.66% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US3596641098
Symbol
FLGT

Fulgent Genetics Stock price

$18.37
+0.30 1.66% 1M
-1.73 8.61% 6M
-10.54 36.46% YTD
-11.78 39.07% 1Y
-84.77 82.19% 3Y
+5.13 38.75% 5Y
+9.19 100.11% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.31 1.66%
ISIN
US3596641098
Symbol
FLGT
Sector

Key metrics

Market capitalization $561.88m
Enterprise Value $355.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.28
P/S ratio (TTM) P/S ratio 2.02
P/B ratio (TTM) P/B ratio 0.49
Revenue growth (TTM) Revenue growth -3.02%
Revenue (TTM) Revenue $277.76m
EBIT (operating result TTM) EBIT $-88.67m
Free Cash Flow (TTM) Free Cash Flow $-28.67m
Cash position $213.07m
EPS (TTM) EPS $-5.53
P/E forward negative
P/S forward 1.99
EV/Sales forward 1.26
Short interest 4.37%
Show more

Is Fulgent Genetics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Fulgent Genetics Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

Buy
33%
Hold
67%

Financial data from Fulgent Genetics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
278 278
3% 3%
100%
- Direct Costs 185 185
8% 8%
67%
93 93
10% 10%
33%
- Selling and Administrative Expenses 107 107
17% 17%
39%
- Research and Development Expense 49 49
28% 28%
18%
-63 -63
39% 39%
-23%
- Depreciation and Amortization 25 25
28% 28%
9%
EBIT (Operating Income) EBIT -89 -89
9% 9%
-32%
Net Profit -165 -165
160% 160%
-59%

In millions USD.

Don't miss a Thing! We will send you all news about Fulgent Genetics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulgent Genetics Stock News

Positive
Seeking Alpha
5 days ago
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Neutral
Seeking Alpha
about 2 months ago
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Li Lu - UBS David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator G...
Neutral
Business Wire
about 2 months ago
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-...
More Fulgent Genetics News

Company Profile

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Head office United States
CEO Ming Hsieh
Employees 1,184
Founded 2016
Website www.fulgentgenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today